Misoprostol is a synthetic analogue of prostaglandin E1. It is used in gynaecology because of its properties of myometrium smooth muscle cells contraction and its effects on the cervix. Misoprostol oral bioavailability is low and several authors have assessed whether the administration by other routes increased its pharmacodynamic effects. This paper summarizes the pharmacokinetic studies after other routes of administration: vaginal, sublingual, buccal or rectal. It also provides an update on its adverse effects and teratogenic effects.
Keywords: Grossesse; Misoprostol; Pharmacocinétique; Pharmacokinectics; Pharmacologie; Pharmacology; Pregnancy; Review; Revue.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.